ATTO
Income statement / Annual
Last year (2025), Attovia Therapeutics Inc.'s total revenue was $1.35 M,
and the percentage change from the previous year is not available.
In 2025, Attovia Therapeutics Inc.'s net income was -$60.63 M.
See Attovia Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
| Period Ended |
12/31/2025 |
12/31/2024 |
| Operating Revenue |
$1.35 M |
$0.00 |
| Cost of Revenue |
$804.00 K
|
$313.00 K
|
| Gross Profit |
$546.00 K
|
-$313.00 K
|
| Gross Profit Ratio |
0.4
|
0
|
| Research and Development Expenses |
$54.15 M
|
$33.86 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.55 M
|
$7.38 M
|
| Other Expenses |
$0.00
|
$0.00
|
| Operating Expenses |
$67.71 M
|
$41.24 M
|
| Cost And Expenses |
$68.51 M
|
$41.55 M
|
| Interest Income |
$6.63 M
|
$3.44 M
|
| Interest Expense |
$0.00
|
$0.00
|
| Depreciation & Amortization |
$804.00 K
|
$313.00 K
|
| EBITDA |
-$66.36 M |
-$41.24 M |
| EBITDA Ratio |
-49.15
|
0
|
| Operating Income Ratio |
-49.75
|
0
|
| Total Other Income/Expenses Net |
$6.53 M
|
$1.75 M
|
| Income Before Tax |
-$60.63 M
|
-$39.80 M
|
| Income Before Tax Ratio |
-44.91
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
| Net Income |
-$60.63 M
|
-$39.80 M
|
| Net Income Ratio |
-44.91
|
0
|
| EPS |
-1.42 |
-1.05 |
| EPS Diluted |
-1.42 |
-1.05 |
| Weighted Average Shares Out |
$43.03 M
|
$43.03 M
|
| Weighted Average Shares Out Diluted |
$43.03 M
|
$43.03 M
|
| Link |
|
|
